26 June 2025
ONDINE BIOMEDICAL INC.
("Ondine Biomedical", "Ondine" or the "Company")
Result of AGM and voting results
Ondine Biomedical (AIM: OBI) announces that all resolutions set out in the Notice of AGM dated 4 June 2025 were duly passed at its Annual General Meeting ("AGM") held on 26 June 2025.
The voting results of the AGM were as follows:
|
| In Favor | Against | Withheld | |||
| Resolution | Votes | % | Votes | % | Votes | % |
| 1. Election of Directors | 305,312,279 | 100.00 | 0 | 0.00 | 0 | 0.00 |
| Carolyn Cross | 305,312,279 | 100.00 | 0 | 0.00 | 0 | 0.00 |
| Nicolas G. Loebel | 305,312,279 | 100.00 | 0 | 0.00 | 0 | 0.00 |
| Jean Charest | 305,312,279 | 100.00 | 0 | 0.00 | 0 | 0.00 |
| Jean Duvall | 302,712,279 | 99.05 | 0 | 0.00 | 2,900,000 | 0.95 |
| Junaid Bajwa | 302,712,279 | 99.05 | 0 | 0.00 | 2,900,000 | 0.95 |
| Margaret Shaw | 305,312,279 | 100.00 | 0 | 0.00 | 0 | 0.00 |
| 2. Appointment of Auditors | 305,312,279 | 100.00 | 0 | 0.00 | 0 | 0.00 |
Enquiries:
| Ondine Biomedical Inc. | www.ondinebio.com |
| Carolyn Cross, CEO | +1 604 669 0555 |
|
Strand Hanson Limited (Nominated & Financial Adviser) |
|
| James Harris, Richard Johnson | +44 (0)20 7409 3494 |
|
|
|
| RBC Capital Markets (Broker) |
|
| Kathryn Deegan | +44 (0)20 7653 4000 |
| |
|
| Vane Percy & Roberts (Media Contact) | |
| Simon Vane Percy | +44 (0)77 1000 5910 |
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.